

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Genetic Technologies Limited</b>
<b>ABN: 17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Nicholas Burrows
<b>Date of last notice</b>	3 June 2020

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	21 December 2020
<b>No. of securities held prior to change</b>	1,670,000 Ordinary shares
<b>Class</b>	Class A Performance Rights
<b>Number acquired</b>	5,000,000
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Performance Rights issued for nil consideration pursuant to resolution 12 approved by shareholders at the Company's 10 December 2020 Annual General Meeting.
<b>No. of securities held after change</b>	1,670,000 Ordinary shares 5,000,000 Performance Rights

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights issued pursuant to resolution 12 approved by shareholders at the Company's 10 December 2020 Annual General Meeting.
---	--

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Genetic Technologies Limited</b>
<b>ABN: 17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Jerzy Muchnicki
<b>Date of last notice</b>	3 June 2020

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<b>MJGD Nominees Pty Ltd</b>
<b>Date of change</b>	21 December 2020
<b>No. of securities held prior to change</b>	<b>MJGD Nominees Pty Ltd</b> 210,436,756 ordinary shares 38,400,000 Ordinary shares (represented by 64,000 American Depositary Receipts)  <b>JGM Investment Group (The Muchnicki Family A/C)</b> 9,400,000 ordinary shares 125,000,000 Unlisted Options  <b>MJGD Nominees Pty Ltd (BSMI A/C)</b> 4,849,129 ordinary shares 6,250,000 Performance Rights
<b>Class</b>	7,500,000 Class A Performance Rights 25,000,000 Class B Performance Rights 25,000,000 Class C Performance Rights

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	57,500,000
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Performance Rights issued for nil consideration pursuant to resolution 13 approved by shareholders at the Company's 10 December 2020 Annual General Meeting.
<b>No. of securities held after change</b>	<b>MJGD Nominees Pty Ltd</b> 210,436,756 ordinary shares 38,400,000 Ordinary shares (represented by 64,000 American Depositary Receipts)  <b>JGM Investment Group (The Muchnicki Family A/C)</b> 9,400,000 ordinary shares 125,000,000 Unlisted Options  <b>MJGD Nominees Pty Ltd (BSMI A/C)</b> 4,849,129 ordinary shares 63,750,000 Performance Rights
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights issued pursuant to resolution 13 approved by shareholders at the Company's 10 December 2020 Annual General Meeting.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Genetic Technologies Limited</b>
<b>ABN: 17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Peter Irwin Rubinstein
<b>Date of last notice</b>	3 June 2020

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Irwin Biotech Nominees Pty Ltd
<b>Date of change</b>	21 December 2020

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<p><b>Irwin Biotech Nominees P/L &lt;BIO A/C&gt;</b>  6,200,000 ordinary shares</p> <p><b>Irwin Biotech Nominees Pty Ltd &lt;BIO A/C&gt;</b>  80,849,310 ordinary shares  5,000,000 Performance Rights</p> <p><b>Irwin Biotech Nominees Pty Ltd</b>  2,000,000 ordinary shares</p> <p><b>Irwin Biotech Nominees Pty Ltd</b>  86,582,700 ordinary shares (represented by  144,305 American Depositary Receipts)</p> <p><b>RIP Opportunities Pty Ltd</b>  7,500,000 ordinary shares (represented by  12,500 American Depositary Receipts)</p> <p><b>RIP Opportunities Pty Ltd &lt;PIR Super Fund A/C&gt;</b>  124,999,999 ordinary shares  125,000,000 Unlisted Options</p>
<b>Class</b>	7,500,000 Class A Performance Rights 25,000,000 Class B Performance Rights 25,000,000 Class C Performance Rights
<b>Number acquired</b>	57,500,000 Performance Rights
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Performance Rights issued for nil consideration pursuant to resolution 14 approved by shareholders at the Company's 10 December 2020 Annual General Meeting.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<b>Irwin Biotech Nominees P/L &lt;BIO A/C&gt;</b> 6,200,000 ordinary shares <b>Irwin Biotech Nominees Pty Ltd &lt;BIO A/C&gt;</b> 80,849,310 ordinary shares 62,500,000 Performance Rights  <b>Irwin Biotech Nominees Pty Ltd</b> 2,000,000 ordinary shares  <b>Irwin Biotech Nominees Pty Ltd</b> 86,582,700 ordinary shares (represented by 144,305 American Depositary Receipts) <b>RIP Opportunities Pty Ltd</b> 7,500,000 ordinary shares (represented by 12,500 American Depositary Receipts)  <b>RIP Opportunities Pty Ltd &lt;PIR Super Fund A/C&gt;</b> 124,999,999 ordinary shares 125,000,000 Unlisted Options
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights issued pursuant to resolution 14 approved by shareholders at the Company's 10 December 2020 Annual General Meeting.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A

+ See chapter 19 for defined terms.



**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Genetic Technologies Limited</b>
<b>ABN: 17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Lindsay Peter Wakefield
<b>Date of last notice</b>	4 June 2020

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Wakko Enterprises Pty Ltd
<b>Date of change</b>	21 December 2020
<b>No. of securities held prior to change</b>	Indirect – Wakko Investments Pty Ltd: 3,750,000 Performance Rights  Indirect - Wakko Enterprises Pty Ltd: 9,418,104 Shares
<b>Class</b>	Class A Performance Rights
<b>Number acquired</b>	5,000,000
<b>Number disposed</b>	Nil

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Performance Rights issued for nil consideration pursuant to resolution 15 approved by shareholders at the Company's 10 December 2020 Annual General Meeting.
<b>No. of securities held after change</b>	Indirect – Wakko Investments Pty Ltd: 8,750,000 Performance Rights  Indirect - Wakko Enterprises Pty Ltd: 9,418,104 Shares
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Performance Rights issued pursuant to resolution 15 approved by shareholders at the Company's 10 December 2020 Annual General Meeting.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

---

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.